

HLA Class II Restricted T-Cell Reactivity to a Developmentally Regulated Antigen Shared by Leukemic Cells and CD34⁺ Early Progenitor Cells

By Tuna Mutis, Ellen Schrama, Simone A P van Luxemburg-Heijs, J H F Falkenburg, Cornelis J M Melief, and Els Goulmy

After allogeneic bone marrow transplantation (BMT), the beneficial graft-versus-leukemia (GVL) effect but also the life-threatening graft-versus-host disease (GVHD) are mediated by T cells of the grafted marrow. The identification of leukemia cell-reactive T cells and their ligands are, therefore, crucial for the development of new anti leukemia strategies. Here we describe a leukemia-reactive allo-HLA class II restricted CD4⁺ T-cell clone, 6.2, isolated from a healthy individual after stimulation with allogeneic leukemic cells. Clone 6.2 recognizes leukemic cells from several AML patients without showing reactivity to unfractionated peripheral blood mononuclear cells, monocytes, B cells, T-cell blasts, and proximal tubulus epithelial cells. Interestingly, clone 6.2

also recognizes BM cells derived from healthy individuals and inhibits the colony formation of myeloid and erythroid cell lineages. In the BM, clone 6.2 recognizes only CD34⁺ early precursor cells but not CD34⁺, more differentiated cells. Thus, the target antigen of clone 6.2 is developmentally regulated and expressed only by leukemic cells and CD34⁺ early progenitor cells in the hematopoietic system. We suggest that targeting the T-cell immune response to leukemia-associated, developmentally regulated antigens of the hematopoietic system can provide a basis for the separation of GVL from GVHD, and may lead to new therapeutic approaches for residual and relapsed leukemia.

© 1997 by The American Society of Hematology.

ALLOGENEIC bone marrow transplantation (BMT) is the therapy of choice for the treatment of several hematologic malignancies, such as leukemia.¹ Today the occurrence of graft-versus-host disease (GVHD) remains a major complication of the BMT.^{2,5} In the current view, both GVHD and graft versus leukemia (GVL) effects of the BMT are mediated by donor derived mature T cells. Depletion of T cells from the BM effectively prevents GVHD, but results in a high rate of leukemia relapses.^{6,8} Furthermore, patients with relapsed chronic myeloid leukemia can be effectively treated by administration of donor lymphocytes.⁹ Several clinical trials show a direct association between GVL and GVHD and suggest that the GVL effect may be the reflection of the antihost reactivity against leukemic cells and is, therefore, not separable from GVHD.^{4,10,11} On the other hand, recent analyses of a large number of patients in the International Bone Marrow Transplantation Register point out that GVL can be observed independent of serious GVHD.¹² Also, results from experimental murine models suggest that GVL and GVHD can be mediated by separate as well as by identical T-cell populations.^{13,16} These data have been also supported by some recent studies in humans where T-cell lines and clones could be isolated, and these preferentially recognized leukemic cells.^{17,22} These in vitro studies, together with the clinical data, suggest that leukemia-associated antigens must exist. Nevertheless, in most cases the isolated T cells appeared not solely leukemia specific or difficult to maintain in vitro.^{18,21}

In our search for T cells that are reactive with leukemia-associated antigens, we have investigated the in vitro T-cell response of a healthy individual against the leukemic cells of an HLA class II mismatched unrelated AML patient with AML M1 classification. We have isolated several T-cell clones, of which the majority was directed against subtle HLA class II differences between the responder and the stimulator. One CD4⁺ proliferative and cytotoxic T-cell clone recognized only leukemic cells from several AML patients in an allo-HLA-DR restricted fashion. This T-cell clone also recognized HLA class II matched BM cells. Neither CD34⁺, more differentiated precursors in the BM nor mononuclear cells in the peripheral blood (PB) are recognized by T cell clone 6.2, suggesting that its target antigen is

expressed only on leukemic cells and on early hematopoietic progenitor cells

MATERIALS AND METHODS

Isolation of PB Mononuclear Cells (PBMcs), Leukemic Cells, and BM Cells

PBMcs or BM cells from healthy donors and acute myeloid leukemia (AML) patients were isolated by Ficoll-hypaque (Pharmacia, Uppsala, Sweden) density centrifugation. Cell samples from AML patients that contained greater than 95% morphologically recognizable leukemic cells were further assigned as "leukemic cells." Leukemic cells, PBMcs, and BM cells were cryopreserved in 10% dimethyl sulfoxide and stored in liquid nitrogen until use.

Isolation of Monocytes, Untransformed B Cells, and BM Cell Fractions

Patients' PBMcs or BM cells from healthy individuals were labeled with the indicated fluorescein-conjugated antibodies (Becton Dickinson). Monoclonal antibody (MoAb)-labeled cells were positively sorted using a fluorescein-activated cell sorter (FACS).

Epstein-Barr Virus-Transformed B Lymphoblastoid Cell Lines (EBV-BLCL)

PBMcs were incubated with EBV during 15 hours at 37°C. After washing, the cells were cultured in RPMI + 20% fetal calf serum (FCS) in the presence of 30 Gy irradiated feeder cells consisting of

From the Departments of Immunohematology and Blood Bank and Haematology, Leiden University Hospital, Leiden, The Netherlands.

Submitted November 12, 1996; accepted March 14, 1997.

Supported by grants from the Dutch Cancer Foundation (Koninkrijk Wilhelmina Fonds) and the J A Cohen Institute for Radiopathology and Radiation Protection (IRS).

Address reprint requests to Tuna Mutis, MD, PhD, Department of Immunohematology and Blood Bank, Leiden University Hospital Bldg1, E3-Q, Box 9600, 2300 RC Leiden, The Netherlands.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.

© 1997 by The American Society of Hematology

0006-4971/97/9003-0025\$3.00/0

PBMCs from six random donors. The EBV-transformed B cells were further expanded in RPMI + 10% FCS.

Phytohemagglutinin (PHA) Blasts

PBMCs were cultured in the presence of 0.1 μ g/mL PHA for 3 days. Activated T-cell blasts (PHA blasts) were further expanded for three days using recombinant interleukin-2 (rIL-2) (20 U/mL) containing culture medium.

Generation of Leukemia-Reactive T-Cell Lines and Clones

Stimulator cells Leukemic cells of an AML patient with AML-M1 subclassification were used as stimulator cells. The HLA typing of the leukemic cells was HLA-A3,-B7,-B62,-Cw7,-DR13(DRB1*1302),-DR15(DRB1*1501), -DR52(Dw26)(-DRB3*0301), -DQw6(DQB1*0602, *0604), -DPB1*0301,*0601.

Responder cells PBMCs of a healthy individual were used as responder cells. The HLA typing of the responder cells was HLA-A3,-B7,-B62,-Cw7,-DR13(DRB1*1301),-DR15(DRB1*1501), -DR52(Dw25)(-DRB3*0202), -DQw6(DQB1*0602,*0603/07), -DPB1*0401,*0402.

Before the induction of primary T-cell cultures, stimulator leukemic cells were cultured for 72 hours with a cocktail of cytokines consisting of 800 U/mL granulocyte-macrophage colony-stimulating factor (GM-CSF, kindly provided by Dr Osanto, Leiden, The Netherlands), 1,000 U/mL IL-4 (Genzyme, Leuven, Belgium), and 150 U/mL tumor necrosis factor- α (TNF- α , Genzyme), in RPMI supplemented with 10% FCS, and antibiotics (penicillin 100 U/mL, streptomycin 100 μ g/mL). A total of 10^7 cytokine-treated, irradiated (30 Gy) leukemic cells were cocultured with 10^7 responder cells in 5 mL of culture medium (RPMI supplemented with 15% human serum [HS] and antibiotics), at 37°C, and 5% CO₂. On day 6 20 U/mL of rIL-2 was added in the culture. On day 8 the T-cell line was restimulated with irradiated leukemic cells. On day 15 the T-cell line was cloned by limiting dilution at 0.3 cells/well in 96-well round-bottom microtiter plates in the presence of a feeder cell mixture containing irradiated PBMCs (30 Gy) from six random donors (1×10^6 cells/mL), irradiated leukemic cells (30 Gy) (2.5×10^5 c/mL), 20 U/mL rIL-2, and 1% Leucoagglutinin-A (Sigma, St Louis, MO). rIL-2, 20 U/mL, was added to the cultures every 72 hours. The T-cell clones were expanded by weekly restimulations with the above-described feeder cell-cytokine mixture and tested for leukemia-specific cytotoxic and proliferative activities.

T-cell proliferation assays One to 2×10^4 responder T cells were cocultured with irradiated stimulator cells (2 to 10×10^5 c/well) in 96-well flat-bottom microtiter plates during 88 hours. Sixteen hours before harvesting the cultures were labeled with 0.5 μ Ci of ³H-thymidine. The ³H-thymidine incorporation was determined by liquid scintillation counting. The results are expressed as the mean of duplicate or triplicate cultures. The SEM of the results never exceeded 15%.

Cytotoxicity assays ⁵¹Cr-labeled target cells (3,000/well) were incubated with serial dilutions of effector T cells in 96-well round-bottomed microtiter plates (Costar 3799, Cambridge, MA). After 4 hours of incubation at 37°C, cell-free supernatants were obtained for gamma counting. The percent specific lysis was calculated as follows: % Specific Lysis = (Experimental Release - Spontaneous Release)/(Maximal Release - Spontaneous Release) \times 100%. Spontaneous release and the maximal release are the chromium release of target cells in culture medium alone and in culture medium containing 1% Triton-X 100 (Fluka, Buchs, Switzerland), respectively.

To use as target cells, proximal tubulus epithelium cells (PTEC) were trypsinized and seeded at 3,000 c/well in 96-well flat-bottom microtiter plates. After allowing adherence, TNF- α (150 U/mL) and interferon- γ (IFN- γ) (200 U/mL) were added to the wells to induce the HLA class II expression. PTEC were cultured in the presence of cytokines for 72 hours. Twelve hours before the assay ⁵¹Cr (3

μ Ci/well) was added to the wells. After washing, ⁵¹Cr labeled, adherent PTEC were used as target cells in cytotoxicity assays.

Hematopoietic precursor cell (HPC) growth inhibition assays HPC growth inhibition assays were performed as described previously.²³ Briefly, 1.25×10^5 bone marrow mononuclear cells (BMMNC) was mixed with effector T cells at different T/BM cell ratios in 0.2 mL of HPC culture medium (Iscove's modified Dulbecco's medium [IMDM] supplemented with 30% plasma, 0.5% bovine serum albumin [BSA], 0.47 g/L transferrin, 5×10^{-5} mol/L mercaptoethanol, and 10% culture supernatant of T cells). The cells were then either immediately resuspended to a final volume of 1.4 mL with semisolid HPC medium supplemented with 10 ng/mL rGM-CSF, 50 ng/mL rIL-3 (both from Sandoz, Basel, Switzerland), 2 IU r-erythropoietin (Cilag AG Int, Zug, Switzerland), and 1.3% methyl cellulose, or briefly centrifuged (1,000g, 15 seconds) to establish BM-T-cell contact and incubated for 4 hours at 37°C in 5% CO₂ before transferring to the semisolid medium. One milliliter of the semisolid suspension was plated in 30-mm plastic dishes and incubated at 37°C in 5% CO₂. After 14 days the number of erythrocyte burst-forming units (BFU-E), colony-forming unit-granulocytes (CFU-G), and CFU-monocytes (CFU-M), defined as typical cell aggregates of more than 20 cells, were scored under an inverted microscope. The percentage HPC growth inhibition is calculated as follows: % HPC Growth Inhibition = (1 - No. of Colonies in the Presence of Effector Cells/No. of Colonies Without Effector Cells) \times 100%.

RESULTS

In Vitro Generation of Leukemia Reactive T-Cell Lines and Clones

The PBMCs of a healthy individual were used to generate in vitro T-cell responses against leukemic cells of an unrelated AML patient. The responder individual and the patient were serologically HLA identical, but showed subtle differences in HLA-DR, -DP, and -DQ genotypings (see Materials and Methods). Before using as stimulator cells, the leukemic cells were cultured with GM-CSF, IL-4, and TNF- α during 72 hours to increase their antigen-presenting capacity. The generated T-cell line showed proliferative and cytotoxic activity against leukemic cells at day 8 (data not shown). Several T-cell clones derived from this T-cell line were tested against leukemic cells, patient's EBV-BLCL, and HLA-typed PBMCs from healthy individuals. Based on the reaction patterns, four types of T-cell clones could be distinguished (Fig 1). (1) The type I T-cell clones (n = 25) were reactive against both leukemic cells and EBV-BLCL. Thus, these clones were not able to discriminate leukemic from nonleukemic cells. (2) The type II T-cell clones (n = 7) were reactive only to EBV-BLCL, suggesting that EBV-associated antigens were recognized. (3) The type III T-cell clones (n = 19) were reactive against leukemic cells but did not show reactivity against patient's EBV-BLCL, suggesting that their target antigen(s) were present on leukemic cells but not on nonleukemic EBV-BLCL. However, when these T-cell clones were tested against a panel of PBMCs, which expressed the mismatched HLA class II antigens of the patient, all T-cell clones recognized one of more PBMCs. Thus, type III T-cell clones were not directed against leukemia-associated antigens, but most probably to alloantigens that were expressed by PBMCs but not by EBV-BLCL.

Specific Recognition of Patient's Leukemic Cells by the CD4⁺ T-Cell Clone 6.2

One remaining CD4⁺ T-cell clone, designated as 6.2, recognized leukemic cells but did not show reactivity against




Fig 1. Specific recognition of original stimulator leukemic cells by the CD4⁺ T-cell clone 6.2. (A) The proliferative activity of different types of T-cell clones against patient's leukemic cells (AML cells), patient's EBV-BLCL, and HLA matched PBMCs. For each type of clone, the reactivity of one representative clone is shown. The number of clones displaying similar reactivity patterns is indicated in the brackets. (B) The proliferative activity of T-cell clone 6.2 against leukemic cells, patient's monocytes, patient's transformed or untransformed B cells, and unrelated PBMC that share HLA class II antigens with the AML patient. CD14⁺ monocytes and CD19/20⁺ B cells were isolated from PBMC of the patient by FACS sorting. Similar results were obtained in at least three independent experiments.

EBV-BLCL, CD19/20⁺ untransformed B cells, or CD14⁺ monocytes that were derived from the PBMCs of the patient (Fig 1B). Furthermore, clone 6.2 did not show reactivity against a panel of PBMCs that shared HLA-class II antigens with leukemic cells (Fig 1B). These results indicated that T-cell clone 6.2 was not directed against antigens expressed by PBMCs, monocytes, or B cells but reacted to an antigen that is expressed only by leukemic cells.

T-Cell Clone 6.2 Is Restricted Via the Allo HLA-DRw26 Molecule

As shown in Fig 2A, the proliferative activity of the clone 6.2 against leukemic cells was completely blocked by MoAb

7.3.19.1 that is directed to HLA-DRB3 locus (HLA-DR52)²⁴. Antibodies directed to HLA class I, HLA-DP, or HLA-DQ^{25,26} were not inhibitory. The MoAb 7.3.19.1 did not inhibit the recognition of the leukemic cells by a control HLA-DP-reactive T-cell clone (Fig 2A, right panel) illustrating its specific inhibitory effect on clone 6.2. Because all cells that are positive for HLA-DRB1*1302 express the DR52 subtype HLA-Dw26 (DRB3*0301), the antigen recognition by clone 6.2 is restricted by HLA-Dw26. Note that the responder cells are also HLA-DR52-positive but are genotypically typed as HLA-DRB3*0202 (see Materials and Methods). Thus, the T-cell clone 6.2 recognizes its leukemia-




Fig 2. T-cell clone 6.2 is restricted by HLA-DRB3 locus product HLA-Dw26 and specifically recognizes HLA-Dw26-positive leukemic cells. (A) Effect of HLA specific MoAbs on the recognition of leukemic cells by T-cell clone 6.2 (left panel) and a control DP reactive T-cell clone (right panel). The target specificities of the MoAbs are indicated in brackets. MoAbs were added in the proliferation assays at 1:100 dilution. ND, not tested. (B) Proliferative activity of T-cell clone 6.2 (left panel) and the HLA-Dw26 specific alloreactive T-cell clone (right panel) against different leukemic and nonleukemic cells. Patients no. 2 and 3 are HLA-Dw26-positive AML-M1 patients; patients no. 4 to 10 are HLA-Dw26-negative AML or ALL patients (3 AML-M1, 1 AML-M3, 1 AML-M5, 1 ALL patient). MoAb 17.3.19.1 is added in the assay. CD14⁺ monocytes from patient no. 2 were obtained from PBMC by FACS sorting. EBV-BLCL and PHA blasts were also tested after culturing with GM-CSF (800 U/mL) + TNF- α (50 U/mL) + IL-4 (500 U/mL) for 72 hours. The thymidine uptake of T-cell clone 6.2 alone and the stimulator cells alone did not exceed 500 cpm.




Fig 3. Specific cytotoxic activity of T-cell clone 6.2 against leukemic cells. Patients no. 1 and 2 are leukemia patients with AML-M1 designation. EBV-BLCL and PHA blasts were also tested after culturing with GM-CSF (800 U/mL) + TNF- α (50 U/mL) + IL-4 (500 U/mL) for 72 hours. Adherent PTEC were prepared as targets as indicated in Materials and Methods. Percent specific release of target cells was determined in 4-hour standard Cr release assays.

associated target antigen in the context of a mismatched, allo HLA-Dw26 (DRB3*0301) molecule

T-Cell Clone 6.2 Proliferates Against Other HLA-Dw26-Positive AML Cells Without Showing Reactivity to Nonleukemic Cells

The T-cell clone 6.2 was subsequently tested against a panel of leukemic and nonleukemic cells derived from different leukemia patients (Fig 2B, left panel). A CD4⁺ alloreactive T-cell clone specific for the HLA-Dw26 molecule was used as control (Fig 2B, right panel). Beside its reactivity against the original stimulator leukemic cells of the AML-M1 patient (no. 1) (Figs 1B and 2A), clone 6.2 recognized two other leukemic cells from AML patients (nos 2 and 3) (Fig 2B, left panel). These leukemic cells were also recognized by the control HLA-Dw26 reactive T-cell clone (Fig 2B, right panel), confirming the expression of HLA-Dw26 on the cell surface. Note that the proliferative activity of both clone 6.2 and HLA-Dw26 specific alloreactive T-cell clone against the leukemic cells of patient no. 2 were blocked by antibody 7.3.19.1, illustrating the HLA-Dw26 dependency of the recognition. Leukemic cells from six HLA-Dw26-negative AML or acute lymphoblastoid leukemia (ALL) patients were not recognized either by clone 6.2 or by the control HLA-Dw26-specific T-cell clone (Fig 2B).

The leukemic cell-specific reactivity of clone 6.2 is further demonstrated by absence of proliferation against different nonleukemic cell types obtained from patients no. 2 and 3. Figure 2B shows that clone 6.2 did not recognize the EBV-BLCL and monocytes derived from patient no. 2, clone 6.2 also failed to recognize PHA blasts or PBMCs derived from the HLA-identical BM donors of patients no. 2 and 3. The EBV-BLCL and PHA blasts that were treated with GM-

CSF/TNF- α /IL-4 cocktail were also not stimulatory, indicating that the target antigen of clone 6.2 was not induced on BLCL or T cells by these cytokines. All tested HLA-Dw26-positive nonleukemic cells, including those that were treated with cytokines, were recognized by the control Dw26-reactive T-cell clone (Fig 2B, right panel), showing that all assayed nonleukemic cells expressed the restriction molecule and were capable of stimulating T cells (Fig 2B, right panel).

T-Cell Clone 6.2 Is Cytotoxic to Leukemic But Not to Nonleukemic Cells

T-cell clone 6.2 not only possessed proliferative activity against leukemic cells but also efficiently lysed the leukemic cells (Fig 3). Similar to its proliferative activity, the cytotoxic activity of clone 6.2 was confined to leukemic cells. Nonleukemic cells such as PHA blasts or EBV-BLCL derived from the patients no. 1 and 2 or from their HLA-identical BM donors were not lysed (Fig 3). BLCL or PHA blasts that were treated with the GM-CSF/TNF/IL-4 cocktail were also not lysed (Fig 3).

To assess whether nonhematopoietic cells can express the target antigen of clone 6.2, an HLA-DRB3*0301-positive PTEC line was tested as target cell (Fig 3). Clone 6.2 and a control alloreactive T-cell line that is directed to HLA-DRB1*1302 and HLA-DRB3*0301 allo-determinants were used as effector cells. Because PTECs do not constitutively express HLA class II, they were cultured with 200 U/mL IFN- γ + 150 U/mL TNF- α during 72 hours to induce HLA class II expression. The control alloreactive T-cell line showed a nonsignificant lysis against untreated PTEC which lacked HLA-class II. The induction of HLA class II expression by IFN- γ and TNF- α led to the recognition of the PTEC




Fig 4. Specific recognition of HLA-Dw26-positive BM early progenitor cells by T-cell clone 6.2. (A) HLA-Dw26-positive or -negative BM cells from healthy individuals were used to stimulate clone 6.2 (left panel) and the control HLA-Dw26-specific alloreactive T-cell clone (right panel) in 88-hour standard proliferation experiments. (B) MoAb 7.3.19.1 is added in the assay. (C) Different subsets of BM cells were obtained by FACS sorting after labeling with appropriate antibodies, irradiated, and used in proliferation experiments as stimulator cells at 5×10^4 cells/well.

by the control alloreactive T-cell line only, suggesting that the PTEC did not express the target antigen of clone 6.2.

T-Cell Clone 6.2 Recognizes CD34⁺ Hematopoietic Progenitor Cells and Inhibits the Growth of Erythroid, Monocytic, and Granulocytic Cell Lineages

T-cell clone 6.2 was tested against a panel of BM cells derived from healthy individuals (Fig 4A, left panel). Likewise, the control HLA-Dw26-specific alloreactive T-cell clone, clone 6.2, recognized all HLA-Dw26-positive BM cells but did not recognize HLA-Dw26-negative BM cells

(Fig 4A). The proliferation of clone 6.2 against BM cells was inhibited by the antibody 7.3.19.1, confirming its HLA-DR-restricted reactivity (Fig 4B). As expected, the PBMC derived from the HLA-Dw26-positive BM donors were not recognized (Fig 4B). These results suggested that the clone 6.2 might recognize a developmentally regulated antigen that is expressed only by early progenitor cells present in the BM. To address this assumption, several FACS sorted BM cell populations were tested for their capacity to stimulate T-cell clone 6.2 (Fig 4C). T-cell clone 6.2 recognized the unsorted BM cells, CD34⁺ early progenitor cells, CD34⁺, CD33⁺ early myeloid cell precursors, but not CD34⁻ cells, including CD34⁻, CD14⁺ monocytic lineage and CD34⁻, CD15⁺ granulocytic cell lineage. These results indicated that the target antigen recognized by the antileukemic T-cell clone 6.2 was expressed by CD34⁺ BM early progenitor cells but not by more differentiated cells, including PBMCs. Note that the control HLA-Dw26-specific alloreactive T-cell clone recognized all cell subsets, indicating that the unresponsiveness of clone 6.2 to CD34⁻ cells was not caused by a lack of stimulatory capacity (Fig 4C, right panel).

Because T-cell clone 6.2 displays cytotoxic activity, we addressed the question of whether it could also lyse BM cells and inhibit the outgrowth of different hematopoietic cell lineages. Therefore, we used BM cells as target cells in cytotoxicity assays (Fig 5) and in parallel we performed HPC growth inhibition assays (Fig 6). A CD8⁺ HLA-A2-specific CTL clone was used as control.

T-cell clone 6.2 showed specific cytolysis against two HLA-Dw26-positive, unfractionated BM cells. As expected, HLA-Dw26-negative BM cells were not lysed (Fig 5, left panel). The moderate levels of lysis observed against these unfractionated BM cells was not surprising because clone 6.2 was expected to recognize only CD34⁺ cells in the BM. The control HLA-A2-specific CD8⁺ alloreactive T-cell clone significantly lysed the BM cells that were HLA-A2-positive (Fig 5, right panel).

In HPC growth inhibition assays (Fig 6), clone 6.2 strongly inhibited the outgrowth of BFU-E, CFU-G, and CFU-M from two HLA-Dw26-positive BM (BM no. 1 and BM no. 2) at T:BM ratios as low as 0.3:1. HLA-Dw26-negative BM (BM no. 10, BM no. 11) were not inhibited, showing that the HPC inhibition was specific and dependent on antigen presentation by BM cells. Likewise, the control HLA-A2-specific CTL inhibited the HPC growth from only HLA-A2-positive BMs no. 1, 10, and 11. Both clone 6.2 and alloreactive T-cell clone inhibited the number of the growing colonies, and no difference in the size of the colonies was observed, suggesting that the further outgrowth of the colonies was not inhibited. Furthermore, neither clone 6.2 nor the CD8⁺ alloreactive clone inhibited the HPC growth when the T cells and the BM cells were only mixed immediately before plating in the semisolid culture medium (data not shown), indicating that the inhibition of HPC growth was dependent to cell-cell contact. These results were similar to those obtained by other CD8⁺ CTL directed to alloantigens or to minor histocompatibility antigens.²³

Taken together, the strong HPC growth inhibition by clone 6.2 may reflect its cytotoxic activity against CD34⁺ early




Fig 5. Cytotoxic activity of clone 6.2 to BM cells. Unfractionated BM cells were tested as target cells for clone 6.2 (left) and for an HLA-A2-specific, CD8⁺ alloreactive CTL (right) in 4-hour standard CML assays.

precursor cells. However, other mechanisms such as induction of apoptosis via fas-fasL interactions cannot be excluded.

DISCUSSION


After an allogeneic BMT mature T cells present in the graft inoculum appear to play a major role in the elimination of residual leukemic cells.^{6,9} The understanding of the nature of the T-cell response directed to leukemic cells and the identification of leukemia-associated T-cell antigens is the basis of new therapeutic methods against leukemia. This issue was the main focus of the present study.

Over the past few years it became clear that the proper activation of naive T-cell precursors in primary *in vitro* cultures requires efficient antigen presentation supported by strong costimulatory signals delivered by the antigen-presenting cell (APC).²⁷ In this respect, leukemic cells may not function as proper APC since they usually lack or weakly express costimulatory molecules such as B7.1 and B7.2. This may be the reason why in some studies antileukemic T-cell lines and clones were reported to be functionally or physically unstable in culture. Therefore, we decided to culture leukemic cells with GM-CSF, IL-4, and TNF- α . These cytokines, which are known to generate adequate APC from monocytes,^{28,30} also increased the antigen-presenting capacity of acute myeloid leukemia cells (manuscript in preparation).

Using this strategy, we investigated primary T-cell responses induced against allogeneic leukemic cells. Beside T-cell clones that were reactive to leukemic cells and patient's EBV-BLCL, we have isolated other alloreactive T-cell clones that recognized leukemic cells, HLA-matched, allogeneic PBMCs, but not patient's EBV-BLCL (Fig 1A, type III clones). These latter T-cell clones are probably directed to allo-HLA determinants, which are apparently absent on EBV-BLCL.

More interestingly, we have isolated a T-cell clone, designated as "6.2," recognizing an antigen present on various leukemic cells but absent on nonleukemic cells isolated from the PB, and on the kidney-derived PTEC. This CD4⁺ T-cell clone appeared to recognize its target antigen not in a self-restricted but in an allo HLA-DR-restricted fashion. In this respect our results are in agreement with previous studies of Sosman et al,^{17,18} who also have shown that allogeneic T cells can display specific antileukemic activity *in vitro*. Similar to the T cells described by Sosman et al, the antileukemic T-cell clone 6.2 described here is CD4⁺, class II restricted, and not only proliferates but also displays cytotoxic activity against leukemic cells. Thus, it is plausible that GVL effect after BMT can be mediated also by antileukemic CD4⁺ T cells. Some recent studies indeed suggest that CD4⁺ T cells can mediate GVL effects without the apparent induction of GVHD.³¹ Moreover, in a recent clinical trial, the GVL effect of the buffy coat transfusion was preserved by the depletion

Fig 6. HPC growth inhibition by T-cell clone 6.2. T-cell clone 6.2 is preincubated with BM cells at indicated T-cell:BM cell ratios for 4 hours at 37°C. The cells were then transferred into semisolid HPC growth medium and cultured in cell culture dishes to allow HPC growth. The colony formation in semisolid medium is determined by light-microscopy after 10 days. Percent inhibition of the HPC growth was determined as follows: % Inhibition = $(1 - \text{No. of Colonies in the Presence of T-Cell Clone} / \text{No. of Colonies in the Absence of T-Cell Clone}) \times 100\%$.



of CD8⁺ cells, whereas the GVHD was largely prevented after this procedure³²

So far little is known about the nature of the leukemia-associated antigens that trigger T-cell immune responses. Several investigators consider leukemia-specific fusion proteins, such as the characteristic BCR-ABL fusion protein in chronic myeloid leukemia (CML), as potential candidates for targeting the T-cell immune response specifically to leukemic cells.³³ Although T cell responses can be generated against the BCR-ABL fusion peptides, it has not been convincingly shown that BCR-ABL fusion product is naturally expressed in the context of HLA molecules. In acute leukemias a variety of tumor-specific chromosome abnormalities occur. Although the fusion products of these chromosomal translocations can be also considered as target antigens for the development of leukemia specific therapies, not a large percentage of patients can be cured by such strategies because of the interindividual variation in the chromosomal abnormalities. However, several of these diverse chromosomal translocations led to the activation of common transcription factors that are important in differentiation.³⁴ As yet it is not known whether these developmentally regulated antigens could trigger T-cell immune responses and serve as leukemia-associated T-cell antigens. Our current results suggest that possibly such developmentally regulated antigens can be recognized by T cells. The HLA-DR restricted T-cell clone 6.2 described here specifically recognizes leukemic cells from several AML patients and reacts to CD34⁺ BM cells without showing reactivity against CD34⁺ BM cells or against nonleukemic cells derived from PBMC. The target antigen of clone 6.2 is also not present on a nonhematopoietic system-derived cell line PTEC. Although we were not able to test other somatic tissue cells, and thus it still remains possible that another cell type can be recognized, so far clone 6.2 shows a very limited target cell specificity in the hematopoietic system. The most likely explanation of this specific target cell specificity is that clone 6.2 recognizes a developmentally regulated antigen of the hematopoietic system, which is involved in the differentiation of early progenitor cells. This antigen is also expressed on leukemic cells that are arrested in an early stage of the differentiation. Because the T cell clone effectively inhibits the outgrowth of hematopoietic precursor cells and lyses the leukemic cells, the use of this clone for the treatment of leukemia after BMT may result in elimination of residual leukemic cells in the PB and their precursors in the BM without the risk of GVHD. The main criticism against such a therapeutic approach is that the T-cell clone 6.2 will also recognize grafted BM and presumably will not allow the outgrowth of several cell lineages. This risk can be avoided by transplantation of an HLA-Dw26-negative, thus a one allele HLA DR mismatched BM graft, because the T-cell clone 6.2 will recognize its target antigen only in the context of HLA-Dw26. It is obvious that in such a transplantation setting the BM graft should be T-cell depleted to avoid the risks of serious GVHD and the rejection of the CTL clone. Alternatively, furnishing the T-cell clone 6.2 with a suicide gene, such as Hsv-tk gene, may allow the control of the T-cell clone in vivo before BMT.

In conclusion, our results suggest that targeting the T cell immune response to the developmentally regulated antigens of the hematopoietic system may be possible, and lead to new approaches in the leukemia treatment.

ACKNOWLEDGMENT

We thank Drs F. Koning and T. Ottenhoff for critical discussions.

REFERENCES

- 1 Sullivan KM. Congress Review. Progress and prospects in bone marrow transplantation. *Transplant Proc* 21:2919, 1989
- 2 Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R. Antileukemic effect of graft versus host disease in human recipients of allogeneic marrow grafts. *N Engl J Med* 300:1068, 1979
- 3 Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host-disease. *N Engl J Med* 304:1529, 1981
- 4 Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Bagder C, Beatty P, Besinger W, Berenson R, Bigelow C, Cheever MA, Clift R, Deeg HJ, Doney K, Greenberg P, Hansen JA, Hill R, Laughran T, Martin P, Neiman P, Peterson FB, Sanders J, Singer J, Stewart P, Thomas ED. Influence of acute and chronic graft versus host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. *Blood* 73:1720, 1989
- 5 Ferrara J, Deeg HJ. Graft-versus-host disease. *N Engl J Med* 324:667, 1991
- 6 Poynton CH. T cell depletion in bone marrow transplantation. *Bone Marrow Transplant* 3:265, 1988
- 7 Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzog RH, Hong R, Masaoka T, Rimm AA, Ringden O, Speck B, Weiner RS, Bortin MM. T cell depletion of HLA identical transplants in leukemia. *Blood* 78:2120, 1991
- 8 Gale RP, Champlin RE. How does bone-marrow transplantation cure leukemia. *Lancet* 2:28, 1984
- 9 Kolb HJ, Mittermüller J, Clemm CH, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. *Blood* 76:2462, 1990
- 10 Weiden PL, Flournoy N, Sanders JE, Sullivan KM, Thomas ED. Anti-leukemic effect of graft-versus-host disease contributes to improved survival after allogeneic bone marrow transplantation. *Transplant Proc* 13:248, 1981
- 11 Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L. The graft-versus-leukemia (GVL) phenomenon. Is GVL separable from GVHD? *Bone Marrow Transplant* 6:155, 1990
- 12 Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B. Graft versus leukemia reactions after bone marrow transplantation. *Blood* 75:555, 1990
- 13 Tutschka PJ, Berkowitz SD, Tuttle S, Klein J. Graft-versus-leukemia in the rat—The antileukemic efficacy of syngeneic and allogeneic graft-versus-host disease. *Transplant Proc* 14:2668, 1987
- 14 Bortin MM, Rimm AA, Saltzstein EC, Rodey E. Apparent independent anti-host and anti-leukemic activity of transplanted immunocompetent cells. *Transplantation* 16:182, 1973
- 15 Bortin MM, Truitt RL, Rimm AA, Bach FH. Graft versus leukemia reactivity induced by alloimmunization without augmentation of graft versus host reactivity. *Nature* 281:490, 1979
- 16 Truitt RL, Shih CY, Lelevre AV, Tempelis LD, Andreani M, Bortin MM. Characterisation of alloimmunisation-induced T lym-

phocytes reactive against AKR leukemia in vitro and correlation with graft-versus-leukemia activity in vivo *J Immunol* 131 2050, 1983

17 Sosman JA, Oettel KR, Hank JA, Fisch P, Sondel PM Specific recognition of human leukemic cells by allogeneic T cell lines *Transplantation* 48 486, 1989

18 Sosman JA, Oettel KR, Smith SD, Hank JA, Fisch P, Sondel PM Specific recognition of human leukemic cells by allogeneic cells II Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells *Blood* 75 2005, 1990

19 van Lochem E, de Gast GC, Goulmy E In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities *Bone Marrow Transplant* 10 181, 1990

20 Falkenburg JHF, Faber LM, van den Elshout M, van Luxemburg-Heijs SAP, Hooftman-den Otter A, Smit WM, Voogt PJ, Willemze R Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation *J Immunotherapy* 14 305, 1993

21 Faber LM, van Luxemburg-Heijs SAP, Willemze R, Falkenburg JHF Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia *J Exp Med* 176 1283, 1992

22 Hoffmann T, Theobald M, Weiss BM, Heimpel H, Heit W Frequency of bone marrow T cells responding to HLA-identical nonleukemic and leukemic stimulator cells *Bone Marrow Transplant* 12 1, 1993

23 Marijt WAF, Veenhof WFF, Goulmy E, Willemze R, van Rood JJ, Falkenburg JHF Minor histocompatibility antigens HA-1, -2, and -4, and HY specific cytotoxic T cell clones inhibit human hematopoietic progenitor cell growth by a mechanism that is dependent on direct cell-cell contact *Blood* 82 3778, 1993

24 Koning F, Schreuder GMTh, Giphart MJ, Bruning JW A mouse monoclonal antibody detecting a DR-related MT2-like specificity Serology and biochemistry *Hum Immunol* 9 221, 1984

25 Spits H, Borst J, Giphart MJ, Coligan J, Terhorst C, de Vries

JE HLA-DC antigens can serve as recognition elements for human cytotoxic T lymphocytes *Eur J Immunol* 14 299, 1984

26 Rebai N, Malissen B, Dieries M, Accolla RS, Corte G, Mawas C Distinct HLA-DR epitopes and distinct families of HLA-DR molecules defined by 15 monoclonal antibodies (mAb) either anti-DR or allo-anti-Ia^k cross reacting with human DR molecule I Cross inhibition studies of mAb cell surface fixation and differential binding of mAb to detergent solubilized HLA molecules immobilized to a solid phase by a first mAb *Eur J Immunol* 13 106, 1983

27 Croft M Activation of naive, memory and effector T cells *Curr Opin Immunol* 6 431, 1994

28 de Waal Malefijt R, Figdor CG, de Vries JE Effects of IL-4 on monocyte functions Comparison to IL-13 *Res Immunol* 144 629, 1993

29 Sallusto F, Lanzavecchia A Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha *J Exp Med* 179 1109, 1994

30 Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G Proliferating dendritic cell progenitors in human blood *J Exp Med* 180 83, 1994

31 Antun JH Graft versus leukemia No longer an epiphenomenon *Blood* 82 2273, 1993

32 Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, Lee M, Gajewski J, van Besien K, Khouri I, Mehra R, Przepiorka D, Korbliing M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation *Blood* 86 4337, 1995

33 Chen W, Peace BJ, Rovira DK, You SG, Cheever MA T cell immunity to the joining region of p210 BCR-ABL protein *Proc Natl Acad Sci USA* 89 1468, 1992

34 Rabbitts TH Translocations, master genes and differences between the origins of acute and chronic leukemias *Cell* 67 641, 1991